Devrim Eren
About Devrim Eren
Devrim Eren is the Director of US Medical Strategy for Ozanimod at Bristol Myers Squibb, with extensive experience in medical affairs and a strong background in immunology and gastroenterology.
Title
Devrim Eren serves as the Director, US Medical Strategy for Ozanimod in the Gastroenterology division at Bristol Myers Squibb.
Company
Devrim Eren is employed at Bristol Myers Squibb, a global biopharmaceutical company known for its medicines in oncology, immunology, and cardiovascular disease.
Professional Background
Devrim Eren has built a robust career in the pharmaceutical industry across various leadership roles. He began as a Medical Science Liaison at Allergan in 2010 and advanced to senior leadership positions. He served as Global Medical Lead for Transplant Immunology at Bristol Myers Squibb from 2019 to 2020 before taking on his current role.
Education and Expertise
Eren has a strong academic foundation with a Ph.D. in Molecular Biology and Genetics from Drexel University College of Medicine, complemented by a Postdoctoral Fellowship at the University of Pennsylvania. His educational background also includes an M.S. in Molecular and Cell Biology from Drexel and a B.S. in Biology from Istanbul University.
Specializations and Skills
Eren is experienced in leading cross-functional medical teams and specializes in medical strategy, competitive intelligence, and lifecycle management. He has notable expertise in immunology and gastroenterology. He excels in KOL relationship management and develops effective post-launch medical plans.
Achievements
Devrim Eren successfully launched Bristol Myers Squibb's first gastroenterology product with a novel mechanism of action into the IBD market during the COVID-19 pandemic. He has led teams in various therapeutic areas, including rare diseases, and is recognized for his proactive problem-solving abilities and effective speaker training in medical affairs.